| Literature DB >> 26742969 |
N Baldev1,2,3, R Sriram1,2,3, P C Prabu1,2,3, A Kurian Gino1,2,3.
Abstract
PURPOSE: Sodium thiosulfate (STS) is clinically reported to be a promising drug in preventing nephrolithiasis. However, its mechanism of action remains unclear. In the present study, we investigated the role of mitochondrial KATP channel in the renal protection mediated by STS.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26742969 PMCID: PMC4756937 DOI: 10.1590/S1677-5538.IBJU.2014.0585
Source DB: PubMed Journal: Int Braz J Urol ISSN: 1677-5538 Impact factor: 1.541
Urine Chemistry.
| Parameters | Normal control | Induction control | Treatment groups | ||||
|---|---|---|---|---|---|---|---|
| STS alone | Diazoxide alone | Glibenclamide alone | Diazoxide+STS | Glibenclamide+STS | |||
| Urea (mg/mL) | 11.12±0.9 | 6.06 ±1.2* | 9.07±1.3 | 10.77±1.5 | 7.33±0.8* | 8.92±1.3 | 10.29±1.5 |
| Creatinine (µm/L) | 12.13±1.4 | 6.26±1.5* | 9.42±0.4 | 8.99±2.9 | 3.94±0.2* | 6.93±1.8* | 7.24±1.5* |
| Calcium (mg/24hr) | 0.95±0.1 | 2.44±0.2* | 1.10±0.3 | 0.69±0.1* | 1.23±0.3 | 1.28±0.2 | 0.60±0.1* |
Group-1 = served as normal control; Group-2 = as a stone induction control; Group-3 = was given STS; Group-4 and Group-5 = were administered diazoxide and glibenclamide respectively and Groups 6 and 7 = were pretreated with diazoxide and glibenclamide respectively half an hour before administration of STS. Data of all results are presented as mean±SD (*) p<0.05, statistically different from normal controls.
serum Chemistry.
| Parameters | Normal control | Induction control | Treatment groups | ||||
|---|---|---|---|---|---|---|---|
| STS alone | Diazoxide alone | Glibenclamide alone | Diazoxide +STS | Glibenclamide +STS | |||
| Urea (mg/dL) | 16.50±0.9 | 41.94±1.1* | 18.76±1.2 | 19.55±1.3 | 29.93±1.2* | 16.42±1.6 | 13.74±1.3 |
| Creatinine (mg/ dL) | 0.35±0.02 | 1.03±0.07* | 0.38±0.02 | 0.35±0.06 | 0.58±0.02* | 0.38±0.04 | 0.35±0.06 |
| ALP (U/L) | 57.03±2.3 | 115.96±2.9* | 49.25±2.4 | 50.73±3.2 | 76.18±2.4* | 70.14±4.2* | 41.39±2.1 |
| Calcium (mg/dL) | 6.21±0.5 | 5.14±0.9 | 4.46±0.7* | 3.34±0.7* | 1.57±0.2* | 4.31±0.7* | 4.10±0.9* |
Group-1 = served as normal control; Group-2 = as a stone induction control; Group-3 = was given STS; Group-4 and Group-5 = were administered diazoxide and glibenclamide respectively and Groups 6 and 7 were pretreated with diazoxide and glibenclamide respectively half an hour before administration of STS. Data of all results are presented as mean±SD (*) p<0.05, statistically different from normal controls.
Lipid peroxidation and antioxidant levels.
| Parameters | Normal control | Induction control | Treatment groups | ||||
|---|---|---|---|---|---|---|---|
| STS alone | Diazoxide alone | Glibenclamide alone | Diazoxide +STS | Glibenclamide +STS | |||
| TBARS (mM/100g tissue) | 1.78±0.1 | 4.21±0.5* | 2.10±0.4 | 0.84±0.09* | 0.74±0.05* | 0.71±0.03* | 0.72±0.08* |
| Superoxide Dismutase (Units/mg protein) | 34.7±4.5 | 17.64±1.2* | 31.24±2.4 | 26.47±1.2* | 25.63±1.3* | 29.91±2.3 | 32.30±2.6 |
| Glutathione peroxidase (µg of GSH utilized/min/ mg protein) | 22±1.2 | 12.13±1.1* | 19.14±1.6 | 15.54±1.3* | 16.66±1.5* | 19.82±1.1 | 19.57±1.4 |
Group-1 = served as normal control; Group-2 = as a stone induction control; Group-3 = was given STS; Group-4 and Group-5 = were administered diazoxide and glibenclamide respectively and Groups 6 and 7 = were pretreated with diazoxide and glibenclamide respectively half an hour before administration of STS. Data of all results are presented as mean±SD (*) p<0.05, statistically different from normal controls.
Figure 1Light microscopic architecture of kidney showing (A) Renal tissue of control (group 1) rats showing no sign of crystal deposition. (B) Renal tissue of urolithiatic rats (group 2) showing crystals deposition and severe obstructive nephropathy (C) Renal tissue of (group 3) STS treated rats showing mild crystal deposition with mild nephropathy. (D) Renal tissue of (group 4) diazoxide treated rats showing mild crystal deposition with moderate obstructive nephropathy (E) Renal tissue of (group 5) glibenclamide treated rats showing prominent crystal deposition with severe obstructive nephropathy (f) Renal tissue of (group 6) diazoxide +STS treated rats showing crystal deposition with severe obstructive nephropathy (g) Renal tissue of (group 7) glibenclamide + STS pretreated rats low crystal deposition with mild nephropathy (h) Crystal's deposition as observed under 40X zoom.
Figure 2Images of agar gel slides and graph representing the percentage inhibition produced by STS in calcium oxalate crystal formation represented as a streak.